ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
10 Gennaio 2024 - 2:06PM
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of patients with renal and inflammatory
diseases who have unmet medical needs, announces that Stephen C.
Glover, Co-Founder, Chairman, Chief Executive Officer, and
President, addressed the 2024 outlook for ZyVersa and the
biotechnology industry in a recent interview on Benzinga All
Access.
To view the segment, click here.
During the interview, Mr. Glover described the significant unmet
need and market opportunity in kidney disease, and how ZyVersa’s
Cholesterol Efflux MediatorTM VAR 200 has the potential to
improve kidney function and reduce kidney disease progression.
Current treatments target glomerular hypertension and inflammation,
but there are no treatments that target lipid accumulation, which
is known to contribute to structural damage, proteinuria, and
progression of kidney disease. ZyVersa plans to initiate a Phase 2a
trial with VAR 200 in patients with diabetic kidney disease (DKD)
in the first quarter of 2024, with preliminary data anticipated by
mid-year 2024.
Mr. Glover also discussed ZyVersa’s proprietary Inflammasome ASC
Inhibitor IC 100, which is designed to block initiation and
perpetuation of damaging inflammation contributing to a multitude
of inflammatory diseases. ZyVersa plans to complete GLP toxicology
studies with IC 100 and submit an Investigational New Drug (IND)
application in the fourth quarter of 2024, followed by initiation
of a Phase 1 trial.
In addition to highlighting ZyVersa’s anticipated 2024
milestones, Mr. Glover offered his views on the renewed optimism in
the biopharma macroeconomic environment in 2024, as evidenced by an
increasingly positive fundraising environment, and upticks in IPOs
and mergers and acquisitions across the industry.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company
leveraging advanced, proprietary technologies to develop
first-in-class drugs. Our focus is on patients with renal or
inflammatory diseases who have significant unmet medical needs. Our
development pipeline includes phase clinical stage Cholesterol
Efflux MediatorTM VAR 200 in development to alleviate damaging
accumulation of cholesterol and lipids in the filtering system of
the kidneys. The lead indication is treatment of rare kidney
disease, focal segmental glomerulosclerosis. VAR 200 has potential
to treat other kidney diseases, including Alport syndrome and
diabetic kidney disease. ZyVersa’s pipeline also includes
proprietary inflammasome ASC inhibitor IC 100 that blocks
initiation and perpetuation of damaging inflammation associated
with a multitude of inflammatory diseases. IC 100 has potential to
treat many different CNS and other inflammatory diseases. For more
information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional financing. A
discussion of these and other factors, including risks and
uncertainties with respect to ZyVersa, is set forth in ZyVersa’s
filings with the Securities and Exchange Commission, including
ZyVersa’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
Corporate and IR ContactKaren CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsCasey
McDonaldcmcdonald@tiberend.com646-577-8520
Dave SchemeliaDschemelia@tiberend.com609-468-9325
Grafico Azioni ZyVersa Therapeutics (NASDAQ:ZVSA)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni ZyVersa Therapeutics (NASDAQ:ZVSA)
Storico
Da Set 2023 a Set 2024